Significance of antimicrobial synergism for the outcome of gram negative sepsis
- PMID: 324279
- DOI: 10.1097/00000441-197703000-00005
Significance of antimicrobial synergism for the outcome of gram negative sepsis
Abstract
Amikacin plus penicillin (A+P) was compared to amikacin plus carbenicillin (A+C) in a double-blind study. Therapy with one of these combinations was given, as soon as servere infection was suspected, to 117 patients with proved gram negative infection, none of whom was granulocytopenic. Gram negative bacteremia was documented retrospectively in 52 patients; 25 had received A+P and 27 had been treated with A+C. All the isolated gram negative pathogens were sensitive to amikacin (MIC less than 12 microng/ml). In the A+P group, 55 per cent of the patients responded favorably while in the A+C group 63 per cent did respond; the difference was more striking for bacteremic patients: 52 per cent responded in the A+P group and 70 per cent in the A+C group. This difference, however, was not statistically significant. The outcome of patients whose infection was treated by synergistic combinations against the offending pathogen was better (66 per cent) than that observed in patients who received nonsynergistic combinations (48 per cent) (p less than 0.05). Once again the results were more striking in the bacteremic patients (p less than 0.01). A favorable outcome was associated also with a high (larger than or equal to 1/8) bactericidal activity of the diluted serum of the treated patient against the offending pathogen (p less than 0.05). This study suggests that the optimal therapy in gram negative septicemia might be the administration of synergistic combinations of antibiotics.
Similar articles
-
Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial.J Infect Dis. 1976 Nov;134 SUPPL:S433-40. doi: 10.1093/infdis/135.supplement_2.s433. J Infect Dis. 1976. PMID: 792359 Clinical Trial.
-
Controlled comparison of amikacin and gentamicin.N Engl J Med. 1977 Feb 17;296(7):349-53. doi: 10.1056/NEJM197702172960701. N Engl J Med. 1977. PMID: 319355 Clinical Trial.
-
Clinical and bacteriological evaluation of amikacin in severe gram-negative infections.J Clin Pharmacol. 1976 Apr;16(4):213-22. doi: 10.1002/j.1552-4604.1976.tb01520.x. J Clin Pharmacol. 1976. PMID: 770510 Clinical Trial.
-
Concept of empiric therapy with antibiotic combinations. Indications and limits.Am J Med. 1986 May 30;80(5C):2-12. Am J Med. 1986. PMID: 3521271 Review.
-
Role of amikacin in the management of intra-abdominal sepsis.Am J Med. 1985 Jul 15;79(1A):28-36. doi: 10.1016/0002-9343(85)90188-3. Am J Med. 1985. PMID: 3895904 Review.
Cited by
-
Combination therapy for treatment of infections with gram-negative bacteria.Clin Microbiol Rev. 2012 Jul;25(3):450-70. doi: 10.1128/CMR.05041-11. Clin Microbiol Rev. 2012. PMID: 22763634 Free PMC article. Review.
-
Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.Antimicrob Agents Chemother. 1980 Sep;18(3):437-42. doi: 10.1128/AAC.18.3.437. Antimicrob Agents Chemother. 1980. PMID: 6252835 Free PMC article. Clinical Trial.
-
Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.BMJ. 2004 Mar 20;328(7441):668. doi: 10.1136/bmj.38028.520995.63. Epub 2004 Mar 2. BMJ. 2004. PMID: 14996699 Free PMC article.
-
Evaluation of novel antipseudomonal drugs using the serum bactericidal activity test.Eur J Clin Microbiol. 1986 Feb;5(1):119-23. doi: 10.1007/BF02013481. Eur J Clin Microbiol. 1986. PMID: 3084241
-
Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants.Eur J Clin Pharmacol. 1988;35(6):637-42. doi: 10.1007/BF00637600. Eur J Clin Pharmacol. 1988. PMID: 3234472
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources